Conversion of a non-selective adenosine receptor antagonist into A3-selective high affinity fluorescent probes using peptide-based linkers by Vernall, Andrea J. et al.
Organic &
Biomolecular Chemistry
PAPER
Cite this: Org. Biomol. Chem., 2013, 11,
5673
Received 28th June 2013,
Accepted 4th July 2013
DOI: 10.1039/c3ob41221k
www.rsc.org/obc
Conversion of a non-selective adenosine receptor
antagonist into A3-selective high aﬃnity ﬂuorescent
probes using peptide-based linkers†
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Advances in ﬂuorescence-based imaging technologies have helped propel the study of real-time biologi-
cal readouts and analysis across many diﬀerent areas. In particular the use of ﬂuorescent ligands as
chemical tools to study proteins such as G protein-coupled receptors (GPCRs) has received ongoing inter-
est. Methods to improve the eﬃcient chemical synthesis of ﬂuorescent ligands remain of paramount
importance to ensure this area of bioanalysis continues to advance. Here we report conversion of the
non-selective GPCR adenosine receptor antagonist Xanthine Amine Congener into higher aﬃnity and
more receptor subtype-selective ﬂuorescent antagonists. This was achieved through insertion and opti-
misation of a dipeptide linker between the adenosine receptor pharmacophore and the ﬂuorophore.
Fluorescent probe 27 containing BODIPY 630/650 (pKD = 9.12 ± 0.05 [hA3AR]), and BODIPY FL-contain-
ing 28 (pKD = 7.96 ± 0.09 [hA3AR]) demonstrated clear, displaceable membrane binding using ﬂuor-
escent confocal microscopy. From in silico analysis of the docked ligand-receptor complexes of 27, we
suggest regions of molecular interaction that could account for the observed selectivity of these peptide-
linker based ﬂuorescent conjugates. This general approach of converting a non-selective ligand to a
selective biological tool could be applied to other ligands of interest.
Introduction
Discrete molecular probes are one mechanism by which a
receptor’s role and function in biological processes can be
interrogated, and as such, rational design-based approaches to
develop these chemical tools are vital. In particular, developing
molecular probes with a high aﬃnity and selectivity for a par-
ticular cell surface receptor target is paramount for unravelling
processes of interest in physiologically relevant systems that
contain mixed receptor subtype populations. G protein-
coupled receptors (GPCRs) are the largest family of transmem-
brane signalling proteins in the human genome and are the
target of 30–40% of currently marketed drugs. Probes that
target these receptors are therefore regarded as extremely valu-
able tools. Unsurprisingly therefore, fluorescent ligands have
been increasingly used in studying GPCRs; for example to
determine receptor expression levels in diseased tissues,1 real-
time receptor–receptor interactions and signaling,2,3 and as a
tracer ligand in a competition binding assay.4 A common
approach to the design and synthesis of receptor probes
involves tethering a known orthosteric binding moiety to a
second ligand or fluorophore via a linker to form a conju-
gate.5,6 It is desirable to develop general methods that can
increase conjugate aﬃnity and selectivity for a target receptor,
especially if a receptor subtype-selective pharmacophore is not
available. Indeed, recent advances in X-ray crystallography of
GPCRs7–11 have further reignited interest in structure-based
design approaches for more selective synthetic ligands.12
From the earlier observations of Jacobson et al.,13 we were
encouraged to investigate whether minor chemical changes to
a peptide-based linker component of a fluorescent ligand con-
jugate could potentially be used to fine tune aﬃnity and/or
selectivity of the final fluorescent probe for a given receptor;
since the linker passes through regions of the receptor capable
†Electronic supplementary information (ESI) available: Experimental details and
characterisation of synthetic compounds, further pharmacological analysis, and
details of the homology modelling and docking. See DOI: 10.1039/c3ob41221k
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of engaging in productive molecular recognition events by the
very nature of the functional group chemistries present there.
In this study, we chose to explore our hypothesis by using the
human A1 adenosine receptor (AR) and hA3AR subtypes as our
model system. The ARs are Class A GPCRs, and there are four
characterised receptor subtypes – the A1, A2A, A2B, and A3.
14
There is growing interest in the A1AR
15 and A3AR
16 as AR drug
targets,17 therefore it remains pertinent to further refine
chemical methods to produce high aﬃnity and selective tools
to probe these receptors. In addition, these receptors are
closely related in terms of amino acid sequence and therefore
pose a significant challenge in terms of designing selective
probes.18
Following the now well established chemical biology prac-
tice of exploiting amino acids in biological conjugates, for
example in drug delivery systems19 and hydrogels,20 we herein
report that the aﬃnity and selectivity of fluorescent conjugates
for the human A1AR versus A3AR can be modulated by single
amino acid changes in a dipeptide linker region connecting
the orthosteric binding moiety and fluorophore. This approach
for increasing aﬃnity and tuning selectivity is likely to have a
broad applicability for developing fluorescent probes for other
biological targets, in particular, ligands for other Class A
GPCRs.
We commenced this study by considering the previously
reported AR fluorescent antagonist 121 alongside the recently
reported 24 (CA200645) (Fig. 1), which are based on the non-
subtype-selective xanthine amine congener (XAC) (3) and are
themselves non-selective for the A3AR/A1AR. Previously, Baker
et al. indicated that when 3 was tethered to diﬀerent fluoro-
phores using the same linker, significant diﬀerences in conju-
gate aﬃnity for the human A1AR were detected.
22 Here we
sought to expand upon this observation by also addressing
receptor aﬃnity and selectivity imparted by subtle changes in
linker composition for conjugates containing the boron-
dipyrromethene moiety. The BODIPY 630/650-X (6-(((4,4-
difluoro-5-(2-thienyl)-4-bora-3a,4a-diaza-s-indacene-3-yl)styryloxy)-
acetyl)amino hexanoic acid) fluorophore was selected based on
previous successes with a number of A3AR and A1AR agonists
and antagonists.4,21–24 However, multicolour imaging appli-
cations are made easier if a range of ligands with varying emis-
sion wavelengths are available, and we were conscious that the
only previously reported example of pharmacophore 3 tethered
to the BODIPY-FL (4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-
s-indacene-3-propionic acid) fluorophore22 exhibited low aﬃnity
for the A1AR and made a poor imaging tool due to substantial
membrane penetration. Therefore in this study we also sought
to optimise the linker component in order to generate a usable
green fluorescent imaging tool with improved receptor aﬃnity.
Results and discussion
Synthesis
We had become increasingly mindful that synthesis of any
fluorescent compound library containing diﬀerent linkers
could become very costly, as large amounts of fluorophore (for
example BODIPY 630/650-X) are often required. We therefore
chose to investigate whether the inexpensive and commonly
available amino-protecting group 9-fluorenylmethyloxycarbo-
nyl (Fmoc) could be employed as an inexpensive alternative for
the hydrophobic BODIPY 630/650 moiety, enabling a ‘pre-
screening’ of the optimal peptide-linker congener prior to
introduction of the expensive fluorophore. As BODIPY 630/650-
X is only commercially available with an internal 6-aminohexa-
noyl linker already present, N-Fmoc-aminohexanoic acid
(Fmoc-Ahx) was proposed as an alternative to BODIPY 630/650-
X in order to mirror the hexanoyl linker present in any final
conjugates. To assess the suitability of this fluorophore substi-
tute approach, commercially available 3 was coupled to
N-Fmoc-aminohexanoic acid using O-(7-azabenzotriazol-1-yl)-
N,N,N′N′-tetramethyluronium hexafluorophosphate (HATU) to
furnish 4 (Scheme 1). The Fmoc-protected congener 5 was syn-
thesised by coupling 3 to N-protected aminopentanoic acid,
followed by N-deprotection and coupling to N-Fmoc-amino-
hexanoic acid. Congener 5 represents the hydrocarbon chain-
length equivalent of the dipeptide moiety we planned to
introduce.
The encouraging pharmacology observed for Fmoc-Ahx-con-
geners 4 and 5 (see later discussion) encouraged us to investi-
gate if replacement of the aminopentanoyl moiety of 5 with a
dipeptide could modulate receptor aﬃnity and/or selectivity.
Our rationale being that introduction of functional side chains
(via the chosen amino acids) would provide additional regions
of molecular interactivity between the conjugate and the
region of receptor space it navigates through. A library of
N-Fmoc-aminohexanoic-dipeptidyl-XAC conjugates was there-
fore synthesised (Scheme 1).
Initially, alanine–alanine (Ala–Ala) linked 6 was synthesised
to ascertain if introduction of a dipeptide maintained aﬃnity
for the AR. As the pharmacology of this ligand confirmed this
was the case, the N-terminal alanine residue from 6 was substi-
tuted with serine (Ser) (7), tyrosine (Tyr) (8), or asparagine
(Asn) (9). The same three substitutions were also performed at
the C-terminal amino acid position, to generate 10, 11, and 12.
The prerequisite for amino acid selection was that the side-
chain functional group should be polar but not requiring a
protecting group for a coupling reaction with a fluorophore-
succinimidyl ester (SE) (Scheme 2). Ser, Tyr, and Asn were
selected as their side-chain functional groups are capable ofFig. 1 Previously reported ﬂuorescent adenosine receptor ligands 121 and 2.4
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hydrogen bonding interactions. Additionally, with Tyr we
could explore potential cation–pi or pi–pi interactions between
the aromatic side-chain and receptor. Based on the observed
structure–activity relationships (Table 1), two other Fmoc-Ahx-
dipeptide-XAC compounds were synthesised; containing a Tyr–
Ser (13) or Tyr–Tyr (14) dipeptide linker.
The Fmoc-Ahx-dipeptide-XAC compounds were not direct
precursors for conjugation to our chosen fluorophore, since
BODIPY 630/650 is commercially available with the aminohexa-
noyl linker pre-installed. Preliminary pharmacological evalu-
ation of the N-Fmoc-aminohexanoyl-dipeptidyl-XAC library
conjugates showed a general trend of higher aﬃnity for the
A3AR rather than the A1AR. Therefore the three dipeptide
linkers that imparted the highest aﬃnity and selectivity for the
A3AR were selected for incorporation into an equivalent
BODIPY 630/650 fluorescent conjugate; Ser–Ala from 7, Tyr–
Ala from 8, and Tyr–Ser from 13. The Ala–Asn dipeptide from
12 was also chosen, as it was one of the least selective Fmoc-
dipeptide-congeners, and thereby allowed us to investigate if
this translated into a comparably non-selective fluorescent
conjugate.
Compounds 15–17 and 18 (intermediates in the synthesis
of 6–14, Scheme 1) were therefore globally deprotected to gene-
rate 20–23 respectively, and coupled to commercially available
BODIPY 630/650-X-SE to aﬀord 24–27 (Scheme 2). For comple-
teness, and to analyse how eﬀectively the aﬃnity and selecti-
vity profile of the Fmoc-Ahx compounds matched the
BODIPY-630/650-X-compounds, Fmoc-containing 19 (the ana-
logous compound to 13 lacking the aminohexanoyl linker) was
also synthesised. Preliminary pharmacological evaluation of
these four BODIPY 630/650 conjugates indicated that 27 pos-
sessed superior selectivity for the A3AR over the A1AR, there-
fore Tyr–Ser-based 23 was additionally coupled to
commercially available BODIPY-FL-X-SE to aﬀord the green
fluorescent conjugate 28.
Pharmacology
Pharmacological characterisation of the compounds was
carried out in Chinese Hamster Ovary (CHO) cells expressing
either the human A1AR (CHO-A1 cells
25), or the human A3AR
and a reporter gene consisting of 6 × cyclic adenosine mono-
phosphate response elements (6 × CRE) promoting the
Scheme 1 Synthesis of Fmoc-Ahx-XAC scaﬀold containing varying linkers. (i) N-Fmoc-Ahx-OH, HATU, N,N-diisopropylethylamine, DMF, 83%; (ii) Three steps from 3,
35% over three steps; (iii) (a) N-Fmoc-amino acid-OH (side-chain protected), HATU, N,N-diisopropylethylamine, DMF; (b). Diethylamine, CH2Cl2; (c) Repeat steps
(a) and (b); (d) Fmoc-Ahx-OH, HATU, DIPEA, DMF; (e) Triﬂuoroacetic acid, CH2Cl2.
Scheme 2 Synthesis of ﬂuorescent dipeptide-XAC conjugates. (i) Diethylamine, CH2Cl2, quantitative. (ii) Triﬂuoroacetic acid, CH2Cl2, quantitative. (iii) BODIPY 630/
650-X-SE, N,N-diisopropylethylamine, DMF; 20 gave 24 (40% after RP-HPLC puriﬁcation), 21 gave 25 (28% after RP-HPLC puriﬁcation), 22 gave 26 (52% after
RP-HPLC puriﬁcation), 23 gave 27 (25% after RP-HPLC puriﬁcation). Or BODIPY-FL-X-SE, N,N-diisopropylethylamine, DMF; 23 gave 28 (25% after RP-HPLC
puriﬁcation).
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expression of a human-secreted placental alkaline phospha-
tase (SPAP; CHO-A3 SPAP cells
23). The aﬃnity of each of the
non-fluorescent compounds (3–14, 19, 23) for the human A1AR
and A3AR was determined in an established fluorescence-
based live cell competition binding assay4 using the fluo-
rescent adenosine receptor antagonist 2 as the labelling ligand
(as detailed in the ESI†).
It was not possible to obtain aﬃnity values of the new
BODIPY 630/650-containing compounds using tracer 2 in this
particular assay as 2 also contained the BODIPY 630/650
fluorophore. Aﬃnity values of all the BODIPY-containing com-
pounds at the A1AR were therefore determined using a [
3H]1,3-
dipropyl-9-cyclopentylxanthine ([3H]DPCPX) whole cell compe-
tition binding assay in CHO-A1 cells. Aﬃnity estimates for the
new BODIPY-containing compounds at the A3AR were initially
obtained by measuring their ability to antagonise agonist-
stimulated functional responses in CHO-A3 SPAP cells. SPAP
levels are driven through the CRE promoter in these cells and
can be used as an indirect measure of cyclic 3′,5′-adenosine
monophosphate (cAMP) levels. The agonist adenosine-5-N-
ethylcarboxamide (NECA) eﬀected a dose-dependent inhi-
bition of forskolin (FSK) stimulated SPAP production in these
cells (ESI Fig. S1†), which was antagonised by all of the fluo-
rescent XAC conjugates (Table 1). It has already been demon-
strated that pKi values obtained with this fluorescence-based
competition binding assay show an excellent correlation to
aﬃnity values measured using diﬀerent assay platforms,4 and
this was confirmed for non-fluorescent compounds 3, 8, 13,
and 19 (ESI Table S2†). In addition, we later show in this
report that, after confirming 28 possessed suitable fluorescent
confocal imaging properties (refer to Confocal Microscopy
section), it could be used as the competing ligand to
measure and cross-validate the aﬃnity of the new BODIPY
630/650-containing ligands for the AR (refer to later discus-
sion, and Fig. 3). All test compounds were confirmed as stable
under the fluorescent binding assay conditions as no signifi-
cant degradation was seen when analysed using reversed-
phase high-performance liquid chromatography (RP-HPLC)
(ESI Fig. S2†).
All of the Fmoc-compounds (4–19), with the exception of 14
at the A1AR, were able to displace the binding of 2 to non-
specific levels at both A1AR and A3AR. The aﬃnity of the
Fmoc-containing conjugate 4 was similar at both receptor sub-
types (pKi ≈ 6.9) and addition of the BODIPY 630/650 moiety
to aﬀord conjugate 1 increased aﬃnity at both receptors and
displayed only marginal A1-receptor selectivity. Likewise,
Fmoc-containing 5 was 3-fold A3-AR selective and displayed a
slightly increased aﬃnity for each receptor subtype on conver-
sion to the BODIPY 630/650 conjugate 2, but maintained a
similar A3AR/A1AR selectivity. These initial examples suggested
that Fmoc-Ahx might potentially be suitable as an alternative
to the BODIPY 630/650-X fluorophore in permitting a cost-
eﬀective pre-screening for optimal linker composition. We
therefore set out to address two questions – (i) can introduc-
tion of a dipeptide moiety in the linker tune the aﬃnity and/or
selectivity of the conjugate, and (ii) does the use of Fmoc in
place of BODIPY 630/650 give a translatable aﬃnity/selectivity
profile for dipeptide-containing conjugate screening?
Table 1 Binding aﬃnities of XAC-derived compounds at human A3AR and A1AR
Compound hA3AR
a,d n hA1AR
b,c,e n Fold Selectivity A3AR/A1AR
g
3 XAC 7.80 ± 0.07a 6 7.30 ± 0.10b 4 3.1
4 Fmoc-Ahx-XAC 6.94 ± 0.06a 5 6.85 ± 0.07b 4 1.2
5 Fmoc-Ahx-pentyl -XAC 7.45 ± 0.12a 4 6.96 ± 0.17b 4 3.1
6 Fmoc-Ahx-Ala-Ala-XAC 7.41 ± 0.15a 4 7.00 ± 0.19b 5 2.6
7 Fmoc-Ahx Ser-Ala-XAC 7.88 ± 0.17a 4 7.02 ± 0.10b 4 7.2
8 Fmoc-Ahx-Tyr-Ala-XAC 8.95 ± 0.06a 4 7.49 ± 0.15b 4 28.8
9 Fmoc-Ahx-Asn-Ala-XAC 7.60 ± 0.17a 4 6.84 ± 0.03b 4 5.7
10 Fmoc-Ahx-Ala-Ser-XAC 7.61 ± 0.15a 5 7.30 ± 0.09b 4 2.0
11 Fmoc-Ahx-Ala-Tyr-XAC 7.69 ± 0.03a 5 6.95 ± 0.10b 4 5.5
12 Fmoc-Ahx-Ala-Asn-XAC 7.35 ± 0.03a 4 7.08 ± 0.07b 4 1.8
13 Fmoc-Ahx-Tyr-Ser-XAC 8.49 ± 0.21a 4 7.66 ± 0.12b 4 6.8
14 Fmoc-Ahx-Tyr-Tyr-XAC 6.80 ± 0.09a 5 61.6 ± 5.2%c 5 —
19 Fmoc-Tyr-Ser-XAC 7.26 ± 0.12a 4 7.04 ± 0.12b 4 1.7
23 Tyr-Ser-XAC 7.27 ± 0.19a 4 6.86 ± 0.13b 4 2.6
1 BODIPY 630/650-X-XAC 7.51 ± 0.21 f 7 8.03 ± 0.14e 7 0.3
2 CA200645 8.38 ± 0.15d 4 7.79 ± 0.07e 4 3.9
24 BODIPY 630/650-X-Ser-Ala-XAC 9.29 ± 0.17d 5 8.39 ± 0.09e 7 8.0
25 BODIPY 630/650-X-Tyr-Ala-XAC 8.41 ± 0.09d 4 7.62 ± 0.11e 4 6.2
26 BODIPY 630/650-X-Ala-Asn-XAC 8.58 ± 0.11d 4 7.82 ± 0.07e 4 5.8
27 BODIPY 630/650-X-Tyr-Ser-XAC 9.12 ± 0.05d 4 7.62 ± 0.13e 4 31.6
28 BODIPY FL-X-Tyr-Ser-XAC 7.96 ± 0.09d 4 6.50 ± 0.04e 4 28.7
a pKi values were calculated from inhibition of the binding of 2 (A3AR Ki = 3.11 nM) to CHO-A3 CRE-SPAP cells.
b pKi values were calculated from
inhibition of the binding of 2 (A1AR Ki = 17.0 nM) to CHO-A1 cells.
c% inhibition of binding of 2 by 10 μM 14. d pKD values were obtained from
global Schild analysis of NECA-mediated inhibition of FSK-stimulated CRE-SPAP responses in CHO-A3 CRE-SPAP cells.
e pKi values calculated
from inhibition of [3H]DPCPX (Ki = 2.0 nM) binding in CHO-A1 cells. All values represent mean ± SEM for n separate experiments performed in
duplicate (a–c) or triplicate (d and e). fDue to apparent non-competitive antagonism at higher concentrations of 1, the pKD value was estimated
from a shift in the NECA concentration response curves to a single concentration of 100 nM of 1 as described in the ESI. g Fold selectivity was
calculated from the Ki (nM) value at A1AR divided by the Ki at A3AR.
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Ala–Ala-linked 6 represented an equivalent congener to 5,
but with the 5-aminopentanoyl moiety of the latter replaced
with a dipeptide. The selectivity profile and aﬃnity of 6 at the
A1AR and A3AR was comparable to 5, demonstrating that this
linker substitution was tolerated but oﬀered no benefit in
relation to either conjugate aﬃnity or selectivity. This result
was encouraging however, since it provided scope to change
the amino acid side-chains in an iterative fashion, and there-
fore an Fmoc-based mini-library was synthesised (Scheme 1).
Changing the N-terminal Ala of 6 to Ser (7), Tyr (8), or Asn (9)
resulted in an interesting spectrum of pharmacological eﬀects.
For 7, the additional side chain hydroxyl resulted in an
increased aﬃnity at the A3AR whilst exerting no significant
change at the A1AR. Taken together, this eﬀected a 4-fold
enhancement in selectivity for the former receptor. With 8,
insertion of the phenol moiety produced an even more pro-
nounced enhancement of A3AR aﬃnity (pKi = 8.95 ± 0.06)
coupled with a modest aﬃnity increase at the A1AR; when
taken together however this ultimately resulted in a 26-fold
increase in A3AR selectivity. For conjugate 9, the observed
improvement in A3AR selectivity is born out of a modest
increase in A3AR aﬃnity coupled with the only example in this
ligand series of a drop in A1AR aﬃnity.
Alternatively, swapping the C-terminal Ala of 6 to Ser (10),
Tyr (11), or Asn (12) resulted in a less pronounced eﬀect on
receptor aﬃnity than the N-terminal amino acid substitution
described above. Of these three compounds, 10 and 11 showed
a small increase in aﬃnity for the A3AR compared to 6, with 12
possessing the lowest A3AR aﬃnity (pKi = 7.35 ± 0.03) of the
Fmoc-Ahx-dipeptide compounds tested. Conjugates 10 and 12
therefore displayed decreased A3AR/ A1AR selectivity profiles;
the former as a result of a marginally greater enhancement of
A1AR aﬃnity compared to A3AR aﬃnity, whereas for 12 it was a
consequence of a modest decrease in A3AR aﬃnity being
coupled with a correspondingly small increase in A1AR aﬃnity.
From the results of these N- and C-terminal iterations, we
elected two additional dipeptide-linked compounds for syn-
thesis; Tyr–Ser containing 13 (N-terminal Tyr-conjugate 8 dis-
played the highest aﬃnity A3AR, whilst the C-terminal Ser-
conjugate 10 displayed the second highest aﬃnity at the A3AR
for their respective 3-ligand series) and Tyr–Tyr containing 14
(N-terminal Tyr-conjugate 8 displayed the highest aﬃnity
A3AR, whilst the C-terminal Tyr-conjugate 11 exhibited the
highest aﬃnity at the A3AR for their respective 3-ligand series).
The Tyr–Ser-linked 13 revealed a modest decrease in A3AR
aﬃnity alongside a slight increase in A1AR aﬃnity when com-
pared to Tyr–Ala-linked 8. Compared to the Ala–Ser-containing
10 however, 13 showed a higher aﬃnity at both receptors and a
5-fold increase in selectivity towards the A3AR. The remaining
dipeptide-conjugate containing Tyr–Tyr (14) showed a substan-
tial loss of aﬃnity for both the A1AR and A3AR compared to 8
and 11. Taken together these results identify a complex inter-
play between each of the two amino acid side-chain contri-
butions to the ultimate observed receptor aﬃnity.
The pharmacology of the Fmoc-Ahx-dipeptide series
demonstrated that inclusion and subsequent amino acid
iteration of a dipeptide linker does indeed influence the
aﬃnity and selectivity of the conjugate towards the A3AR and
A1AR. Before investigating if an Fmoc-dipeptide conjugate
library is a good predictor of the pharmacological properties of
the corresponding BODIPY 630/650 conjugates, we first con-
sidered the influence of the Ahx linker and Fmoc group in a
Fmoc-Ahx-dipeptide conjugate. A Tyr–Ser-congener without the
Ahx linker (19) and another with a free N-terminus (23) were
synthesised. Congeners 19 and 23 both showed very similar
receptor subtype aﬃnities and hence selectivities, yet a sub-
stantial reduction in aﬃnity for the A3AR and a minor drop in
aﬃnity for the A1AR when compared to Fmoc-Ahx-linked 13.
This suggests that the potentially protonated N-terminus of 23
may not be a significant factor in the loss of AR aﬃnity com-
pared to 13, but rather the lack of an “optimally positioned”
Ahx and/or Fmoc moiety.
The Fmoc-dipeptide based mini-compound library
members (6–14) showed a general trend of A3AR selectivity
over the A1AR. The three Fmoc-compounds that possessed the
highest A3AR aﬃnity and selectivity (Ser–Ala 7, Tyr–Ala 8 and
Tyr–Ser 13) were subsequently selected for conversion of the
Fmoc moiety to BODIPY 630/650 (giving 24, 25, and 27 respect-
ively). The Fmoc moiety of the compound with the lowest A3AR
aﬃnity and minimal selectivity (Ala–Asn-12) was also
exchanged with BODIPY 630/650 to give 26, to ascertain if the
non-selective and lower aﬃnity profile of 12 was faithfully
translated into the fluorescent conjugate. Parallel shifts in the
agonist concentration-response curves at the A3AR were
observed for fluorescent XAC-conjugates 2 and 24–27 (Table 1,
ESI Fig. S2†), with a Schild slope value not diﬀering from
unity; indicating that they act as competitive antagonists.
However non-parallel shifts in the NECA concentration-
response curves were observed in the presence of the pre-
viously reported 1, suggesting non-competitive antagonism at
the A3AR. In a [
3H]DPCPX whole cell binding assay all com-
pounds (2, 24–27) including 1 could displace radio-ligand
binding to non-specific levels, indicating that they were
binding to the same site on the A1AR.
BODIPY 630/650 conjugate 24, containing the Ser–Ala
linkage, displayed the highest aﬃnity for both the A3AR (pKD =
9.29 ± 0.17) and A1AR (pKi = 8.39 ± 0.09) of all the compounds
in this study. There was a substantial increase in the aﬃnity of
24 (1.4 log unit increase in pKi at each receptor) compared to
Fmoc-analogue 7. The selectivity profile was reproduced, with
both 24 and 7 showing 7- and 8-fold A3AR/A1AR selectivity
respectively. An enhanced A3AR and A1AR aﬃnity of the
BODIPY 630/650 conjugate compared to the Fmoc analogue
was also observed for the 4/1 and 5/2 compound pairs. It is
interesting to note this gain in aﬃnity by the presence of
BODIPY 630/650 has also been observed for other fluorescent
AR ligands, for example quinoxaline-based antagonists23 and
even for agonist-based conjugates.24 Tyr–Ala-linked 25 was the
only BODIPY 630/650-conjugate that had a reduced aﬃnity
(0.5 log unit decrease) for the A3AR compared to the corres-
ponding Fmoc-compound (8). Therefore since the A1AR
aﬃnity of 25 was unchanged, there was a resultant decrease in
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A3AR selectivity from 29-fold to 6-fold. The Ala–Asn dipeptide
was chosen based on 12 being the least selective of all the
Fmoc-Ahx-dipeptide compounds. When Ala–Asn was incorpor-
ated into BODIPY 630/650 conjugate 26, again its aﬃnity
increased and its A3AR selectivity shifted from 2-fold to 6-fold.
The BODIPY 630/650-conjugate with the greatest A3AR selecti-
vity (32-fold) was Tyr–Ser-linked 27 (A3AR, pKD = 9.12 ± 0.05;
A1AR, pKi = 7.62 ± 0.13) (Fig. 2). Compared to Fmoc-containing
13, 27 retained a similar aﬃnity for the A1AR but an increased
aﬃnity for the A3AR, thereby improving its A3AR selectivity. A
comparison of the BODIPY 630/650-peptide conjugates
(24–27), highlighted the significant eﬀect of the dipeptide
linker composition on their pharmacological profile, as pre-
viously observed for the Fmoc-dipeptide compound series
(6–14).
Returning to our original hypothesis, iterative chemical
changes in the linker component of a conjugate can therefore
be used to fine tune aﬃnity and/or selectivity for a given recep-
tor. However results obtained in this study clearly suggest that
the Fmoc-conjugate pharmacology does not reliably predict
the corresponding BODIPY 630/650-conjugate pharmacology.
It is interesting to note though that in the majority of cases,
addition of the BODIPY fluorophore increased the aﬃnity by
more than 3-fold; adding further substance to the hypothesis
that the fluorophore is implicated in some form of exosite
binding, with a significant influence on overall ligand aﬃnity
for the receptor. It is highly likely that the BODIPY fluorophore
is sampling diﬀerent AR residues to the Fmoc moiety. Indeed,
when one considers the molecular overlay of the two groups it
is conceivable that the Fmoc portion could be interacting with
Fig. 2 Live cell confocal imaging of the human A3AR expressed in CHO cells using (a) 24 (b) 27 (c) 28 and compared to (d) the non-peptide linked 1. CHO-A3 SPAP
cells were incubated with ﬂuorescent ligand for 30 min at 22 °C in the absence (left columns) or presence (right columns) of MRS1220. Single equatorial confocal
images (BODIPY 630/650 or BODIPY FL) and their corresponding transmitted light images (Transmitted Light, lower rows) were obtained in the continued presence
of the ﬂuorescent ligand and/or unlabelled antagonist. For each compound, images in the presence and absence of MRS1220 were obtained using identical settings
for laser power, detector oﬀset and gain. Images shown are from a single experiment representative of 3–5 performed. Scale bars = 20 μm.
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similar AR residues to the styryl group that is contained within
the BODIPY 630/650 entity.
Since conjugate 27 was our leading fluorescent compound
in terms of the maximum A3AR selectivity, we incorporated the
same Tyr–Ser linker into a BODIPY-FL conjugate to furnish 28
(Scheme 2, Table 1). Previous attempts in our laboratory to
construct a BODIPY-FL-containing AR fluorescent tool have
been unsuccessful. For example Baker et al.22 reported that a
conjugate of 3 linked to BODIPY-FL via an 8-(2-aminoethyla-
mino)-8-oxooctanoyl spacer showed no displacement of [3H]
DPCPX specific binding at concentrations up to 10 μM in a
CHO-A1 whole-cell binding assay. Utilising our new peptidic-
linker approach, BODIPY-FL conjugate 28 showed an aﬃnity
for the A3AR (A3AR, pKD = 7.96 ± 0.09) that was acceptable and
promising in terms of an exploitable fluorescent probe for
imaging, albeit with a reduced aﬃnity for the A3AR and A1AR
compared to both 13 and 27. The 29-fold A3AR/A1AR selectivity
of 28 was similar to the 32-fold selectivity observed for the
equivalent BODIPY 630/650 conjugate (27).
Live cell confocal microscopy
The measured A3AR aﬃnity of 24, 27, and 28 does not necess-
arily imply that these conjugates will be useful as fluorescent
probes for the A3AR, as the physiochemical and photochemical
properties must also be appropriate. A good fluorescent ligand
must show low levels of nonspecific membrane binding, should
not significantly diﬀuse into the cell cytosol and should have a
suﬃciently high quantum yield when bound to the receptor to
provide a good signal to noise ratio when imaged.
We therefore used confocal microscopy to examine the
ability of 24, 27 and 28 to detect the human A3AR in CHO-A3
SPAP cells, and in particular to compare their imaging pro-
perties to those of our original non-peptide conjugated XAC-
derivative 121 (Fig. 2). In each case, CHO-A3 SPAP cells were
incubated with fluorescent ligand at a concentration equi-
valent to its KD for the receptor (Table 1) to ensure equivalent
receptor occupancies. Following incubation of CHO-A3 SPAP
cells with 0.5 nM 24 and 1 nM 27 for 30 min, strong defined
membrane fluorescence was seen, whilst levels of intracellular
fluorescence remained low (Fig. 2a,b). The bulk of the
observed membrane binding was to the A3AR, since when cells
were pre-treated with the non-fluorescent A3AR antagonist
MRS1220, the binding was significantly reduced. The conju-
gate 28 containing the BODIPIY-FL fluorophore also produced
clear distinct and displaceable membrane binding. In com-
parison to the dipeptide-linked conjugates (24, 27, 28), whilst
a 30 min incubation with 1 also produced significant and
bright membrane-localised fluorescence, there was also sub-
stantially more cytoplasmic fluorescence. This was particularly
evident in cells pre-treated with MRS1220, where the mem-
brane-localised fluorescence was prevented, but there was a
substantial increase in cytoplasmic signal (Fig. 2d).
Fluorescent binding assay using compound 28
The success of 24, 27 and 28 as fluorescent chemical tools for
the A3AR demonstrates that this design-based approach of
using side-chain functionalised peptidic linkers has signifi-
cant benefits over non-peptidic linkers. In addition to tuning
the aﬃnity and selectivity of the conjugate, the increased
levels of specific membrane binding at the low concentrations
and the propensity of the compounds to remain localised to
cell membrane even after extended incubation is a significant
advantage over earlier non-peptidic fluorescent derivatives of 3
(for example 1). Because of the refined imaging properties,
now for the first time we were able to use a green ligand, 28, as
the tracer ligand in place of the previously employed 2
(Table 1) in an analogues competition binding assay (Fig. 3).
This enabled measurement of the aﬃnity values for the new
BODIPY 630/650-containing compounds (24, 25, 27) for the
A3AR using 28 as the tracer, as there is a large separation in
the excitation/emission wavelengths of the BODIPY FL and
BODIPY 630/650 fluorophores.
Clear concentration-dependent displacement of 28 by
increasing concentrations of 24, 25 and 27 was observed,
which enabled generation of competition binding curves and
estimation of pKi values (pKi = 8.96 ± 0.03, 8.20 ± 0.06, 8.70 ±
0.10 for 24, 25 and 27 respectively (Fig. 3a i–iii, 4b). The pKi
values measured for 24, 25 and 27 using 28 as the competing
tracer are of the same order of magnitude as the values
obtained for 24, 25, and 27 at the A3AR in the CRE-SPAP gene
transcription assay (Table 1). Using the same competition
assay that was originally used to analyse the Fmoc-based com-
pounds with tracer 2 (Table 1) the aﬃnity of the BODIPY FL-
labelled 28 for the A3AR was also determined (pKi = 7.55 ±
0.19) (Fig. 3a iv, 3c), and again showed good correlation with
the A3AR CRE-SPAP measurements (Table 1).
Molecular modelling
Molecular modelling of the A1AR and A3AR as well as docking
of the BODIPY 630/650-containing compounds 27 and 26
(greatest and least A3AR/A1AR selectivity respectively) was
carried out in an attempt to rationalise the pharmacological
data obtained in this study in terms of the selectivity imbued
by the peptide linker. The homology models for the two pro-
teins (see ESI Fig. S3–S6, Tables S3–S4†) were generally quite
similar, however in the A3AR model the extracellular end of
helix I was predicted to be further away from the neighbouring
helix VII, generating a cleft and groove that was absent in the
A1AR model (Fig. 4) and as is discussed below, this diﬀerence
proved to be significant.
Docking of 27 to the A1AR failed to reveal a single high-
scoring pose. While the XAC-component of the molecule
remained in its crystallographic position, the dipeptide linker
and terminal BODIPY sampled a variety of alternative confor-
mations, none of which featured particularly significant
ligand–protein interactions, and all of which placed the
BODIPY moiety in a rather solvent-exposed environment
(Fig. 5a). However for the A3AR, docking of 27 produced a
clear single cluster of poses (Fig. 5b) which revealed similar
interacting regions within the pocket and featured the dipep-
tide/BODIPY portion exiting through the transmembrane (TM)
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I/ TM VII cleft and groove to the space otherwise occupied by
the aliphatic chains of the membrane lipids (ESI Fig. S7†).
Docking of 26 to both the A1AR and the A3AR provided
some rationalisation for why this compound possesses the
lowest A3AR/A1AR selectivity. Only two poses could be gener-
ated for 26 bound to A1AR (Fig. 5c) and three for it bound to
A3AR (Fig. 5d). In neither case was a single, well-defined
binding mode identified, nor was the BODIPY portion buried
deep in the lipid bilayer. In the absence of single, well-defined
predictions for the binding poses it is not appropriate to make
detailed analyses of how the various structural features in
these two proteins and ligands contribute to the patterns of
aﬃnity and selectivity, however some general insights are poss-
ible. Primarily, the cleft and groove between helices I and VII
of the A3AR may provide an opportunity for a suitably designed
fluorescent ligand to bury its fluorophore in the lipid environ-
ment in a way much harder to achieve for the A1AR. For
eﬀective binding to the A3AR the nature of the dipeptide linker
is important for two separate reasons. Firstly, the amino acids
present in the ligand should have suitable functionality to
interact with the protein in the region of the cleft and groove.
Secondly, the docking studies suggest that the dipeptide
moiety of the conjugate is quite exposed to the surrounding
environment as it exits the protein and this environment
includes areas within the lipid bilayer, and in close proximity
to the phospholipid headgroups. Interestingly, it has been
established that certain amino acids, such as serine and in
particular tyrosine, have a greater propensity to feature in this
environment26 while in contrast amino acids such as aspara-
gine are not as favourable.
Fig. 3 Measurement of the aﬃnity of 24, 25, 27 and 28 at the A3AR using a ﬂuorescence based competition binding assay. (a) Representative montages of images
of CHO-A3 SPAP cells with increasing concentrations of 24 (i), 25 (ii) or 27 (iii) using tracer 28 and BODIPY-FL ﬂuorescence measured; or with increasing concen-
trations of 28 (iv) using tracer 2 and BODIPY 630/650 ﬂuorescence measured. Competition curves generated from the total BODIPY FL (b) or BODIPY 630/650
(c) image intensity. Data are normalised to maximal 28 (b) or 2 (c) ﬂuorescence in the absence of any competing ligand. Each data point represents the mean ± SEM
from four (24), ﬁve (25, 27 and 28) or six (d) experiments performed in duplicate.
Fig. 4 Comparison of the homology models of the A1AR (yellow) and A3AR
(green), highlighting the diﬀerent positions of the extracellular ends of helix I
(red for A1AR, cyan for A3AR). For the latter protein this results in the formation
of a cleft and groove at the interface with helix VII (grey for A1AR, pink for
A3AR) that is absent in the A1AR model.
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Conclusions
A key feature of the current state of research into GPCRs is an
increasing awareness of the need to scrutinise their cellular
location and involvement in complex signalling interactions.
As such, fluorescence-based approaches have developed apace
to meet these needs.27 The necessity to supply high quality
fluorescent ligands as chemical tools to study this important
area of bioanalysis therefore remains a primary research
goal.28 The methods applied to fluorescent ligand chemical
synthesis have matured significantly and this study has further
highlighted the important contribution of the linker to the
overall pharmacology of fluorescently labelled GPCR ligands.
Specifically we have shown that the non-selective A1AR and
A3AR antagonist 3 can be used as the parent ligand to ulti-
mately generate higher aﬃnity and subtype-selective fluo-
rescent probes (for example 27 and 28) using advantageous
amino acid selection within a dipeptide linker.
We have also demonstrated that fluorescent ligand
measurements can be undertaken using live cells with ligands
conjugated to spectrally separated fluorophores. This allowed
aﬃnity data to be obtained for each ligand using the alter-
native as the competing probe. In silico analysis of
BODPIY-630/650-X dipeptide-conjugates docked into homology
models of the A1AR and A3AR has identified potential sites of
molecular interaction between the peptidic linker moiety and
the receptor, which may help rationalise their observed selecti-
vity. For GPCRs where there are no subtype discriminating
orthosteric ligands to select as a starting point for conjugate
synthesis, the methods established here could prove even
more valuable for the design of sub-type selective fluorescent
probes. One could postulate that further SAR refinement of the
dipeptide sequence, or extending the peptide length may
impart even greater subtype selectivity and this is the on-going
focus of work within our laboratories.
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Fig. 5 Docking of ﬂuorescent conjugates using Glide into the AR homology models. (a) Five poses generated for 27 in A1AR, (b) six poses generated for 27 in
A3AR, (c) two poses generated for 26 in A1AR, (d) three poses generated for 26 in A3AR. The phosphorus atoms of the POPC upper leaﬂet headgroups are shown in
orange, to mark the water–lipid interface.
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